← Back to Search

Anti-androgen

VERU-100 for Prostate Cancer (VERU-100 Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Veru Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 and day 91
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing VERU-100, a new drug, to see if it can lower and maintain low testosterone levels in men with advanced prostate cancer. By reducing testosterone, the drug aims to control the progression of the cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 and day 91
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 and day 91 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent of men with total testosterone at <50 ng/dL by day 28
Secondary study objectives
Total testosterone below 20ng/dL levels on VERU-100

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VERU-100 at various dosesExperimental Treatment1 Intervention
2 ml, 2.5 ml, 3 ml, 3.5 ml of VERU-100

Find a Location

Who is running the clinical trial?

Veru Inc.Lead Sponsor
10 Previous Clinical Trials
728 Total Patients Enrolled
BernetteStudy ChairVeru Inc.
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top